University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Susan M. Chang, MD

Susan M. Chang, MD

Professor in Residence, Department of Neurological Surgery, UCSF
Co-Leader, Neurologic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center

Lai Wan Kan Endowed Chair, UCSF

Cancer Center Program Memberships

Neurologic Oncology

Research Summary

My research interest is in the development of novel therapies for patients with brain tumors, as well as the assessment of novel imaging biomarkers in the management of patients. I am the principal investigator and co-investigator on more than 15 active clinical trials that evaluate the wide spectrum of therapeutic interventions that span chemotherapy, targeted agents, immunotherapy and convection enhanced delivery of novel agents. I am the site PI of an NIH-funded adult brain tumor consortium and serve on the coordinating committee for that entity. I have served as a member of the Board of Scientific Directors and currently am a member of the Brain Malignancy Steering Committee and the Developmental Therapeutics Study Section at the NIH. I am the program leader for the Neuro-Oncology Program at the Helen Diller Family Comprehensive Cancer Center. I am the PI of a P01 grant related to integrating advances in physiologic and metabolic imaging with tissue biomarkers in order to optimize the management of patients with glioblastoma (GBM). For the UCSF Brain Tumor SPORE, I am the clinical co-PI of the overall grant, a member of the Executive Committee, the co-Director of the Biostatistical and Clinical Core and a co-Leader of a SPORE Project evaluating the role of physiologic imaging in the determination of malignant progression of low-grade glioma.

Education

University of British Columbia, 1981
University of British Columbia, MD, 1985, Medicine
Pasqua Hospital, University of Saskatchewan, Regina, Internship, 1985-1986
Plains Health Centre, Regina, Saskatchewan, Residency, 1986-1987
Toronto General Hospital, U of Toronto, Ontario, Residency, 1987-1989
Princess Margaret Hospital, U of Toronto, Ontario, Residency, 1989-1991
Royal College of Physicians & Surgeons, Canada, FRCPS, 1990, Internal Medicine
Royal College of Physicians & Surgeons, Canada, FRCPS, 1991, Medical Oncology


Professional Experience

  • 1991-1992
    Lecturer, Department of Medicine, University of Toronto, Ontario
  • 1991-1992
    Director of Palliative Care, Department of Medicine, St Michael's Hospital, Toronto, Ontario
  • 1992-1994
    Clinical Instructor, Neuro-Oncology Program, Brain Tumor Research Center, Department of Neurological Surgery, UCSF
  • 1994-1996
    Assistant Clinical Professor, Neuro-Oncology Program, Brain Tumor Research Center, Department of Neurological Surgery, UCSF
  • 1994-present
    Member, Brain Tumor Research Center, Dept. of Neurological Surgery, School of Medicine, UCSF
  • 1996-1998
    Assistant Professor in Residence, Dept. of Neurological Surgery, School of Medicine, UCSF
  • 1998-2004
    Associate Professor in Residence, Dept. of Neurological Surgery, School of Medicine, UCSF
  • 2003-present
    Vice Chair of Clinical Enterprise, Department of Neurological Surgery, UCSF
  • 2004-present
    Professor in Residence, Dept. of Neurological Surgery, School of Medicine, UCSF
  • 2005-present
    Director, Division of Neuro-Oncology, Department of Neurological Surgery, UCSF
  • 2013-present
    Director, Gordon Murray Neuro-Oncology Caregiver Program
  • 2014-present
    Editor in Chief of Neuro-Oncology Practice
  • 2015-present
    Program Leader, Neuro-Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center

Honors & Awards

  • 2014
    UCSF Voice of the Patient Pinnacle Award x 7 years, Press Ganey award for excellence in patient care per division, Hall of Fame
  • 2014
    John J. Mealey Jr. Neuro-Oncology Lectureship

Selected Publications

  • selected from over 133 publications
  • Chan AA, Lau A, Pirzkall A, Chang SM, Verhey LJ, Larson D, McDermott M, Dillon W, Nelson SJ : 1H MRSI as a tool for evaluating grade IV glioma patients undergoing gammaknife radiosurgery J of Neurosurgery 101:467-75, 2004
  • Chang S, Parney I, Huang W, Asher T, Bernstein M, Lillehei K, Brem H, Berger M, Laws E and the Glioma Outcomes Project Investigators : Patterns of care for adults with newly diagnosed malignant gliomas: data from the Glioma Outcomes (GO) Project. JAMA 293:557-564, 2005
  • Parney IF, Kunwar S, McDermott M, Berger M, Prados M, Cha S, Croteau D, Chang S : Neuroradiographic changes following convection enhanced delivery of the conjugated toxin IL-13-PE38QQR for recurrent malignant glioma. J Neurosurgery 102:267-275, 2005
  • Butowski N, Prados M, Lamborn K, Larson D, Sneed P, Wara W, Malec M, Rabbitt J, Page M, Chang S : Phase II study of concurrent temodar and cis-retinoic acid with radiation for adult patients with glioblastoma multiforme In J Rad Oncol Biol Physics 61(5): 1454-1459, 2005
  • Parsa AT, Wacchorst S, Lamborn K, Prados M, Berger M, Chang S Prognostic significance of intracranial dissemination in adult glioblastoma multiforme J Neurosurg 102:622-628, 2005
  • Li X, Vigneron DB, Cha S, Graves EE, Crawford F, Chang SM, Nelson SJ : Relationship of MR-Derived Lactate, Mobile Lipids, and Relative Blood Volume for Gliomas in Vivo. AJNR 26(4): 760-769, 2005
  • Gomez DR, Missett BT, Wara WM, Lamborn KR, Prados MD, Chang S, Berger MS, Haas-Kogan DA : High failure rate in spinal ependymomas with long-term follow-up. Neuro-Oncology 7, 254-259, 2005
  • Chang SM, Y Wen PY, Cloughesy T, Conrad C, Fink K, Robins HI, De Angelis L, Razier J, Lamborn KR, Kuhn Dancey J, Prados MD : Phase II study of CCI-779 in recurrent glioblastoma multiforme. Invest New Drugs 23 (4): 357-361, 2005
  • Smith J, Cha S, Mayo K, McDermott M, Parsa A, Kunwar S, Chang S, Dillon W, Prados M, Berger M : Serial diffusion-weighted MR imaging in glioma: distinguishing tumor recurrence from post-resection injury. J Neuro-surgery 103:428-438, 2005
  • Lupo JM, Cha S, Chang SM, Nelson SJ : Dynamic susceptibility-weighted perfusion imaging of high grade gliomas: characterization of spatial heterogeneity. AJNR 26:1446-54, 2005
  • Lee MC, Cha , Chang SM, Nelson SJ : Dynamic susceptibility contrast perfusion imaging of radiation effects in normal appearing brain tissue:changes in the first pass and recirculation phases JMRI 21:683-693, 2005
  • Cha S, Tihan T, Crawford F, Fischbein N, Chang S, Bollen A, Nelson S, Prados M, Berger M, Dillon W : Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR Imaging AJNR 26:266-73, 2005
  • Chang SM, Reynolds SL, Butowski NA, Lamborn KR, Buckner JC, Kaplan RS, Bigner DD : GNOSIS- guidelines for neuro-oncology-standards for investigational studies. Reporting of phase I/II clinical trials. Neuro-Oncology 7: on line 05-055, August 25, 2005
  • Cloughesy TF, Kuhn J, Robins IH, Abrey L, Wen P, Fink K, Lieberman F, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Wright J, Lamborn K, Sebti S, Prados M : A phase I trial of Tipifarnib in patients with recurrent malignant glioma taking EIAEDs: A NABTC study. J Clin Oncology 23:6647-6656, 2005
  • Chang SM, Barker FGII. Marital status, treatment and survival in glioblastoma multiforme: a population-based study.Cancer 104:1975-84, 2005
  • Lassman AB, Rossi MR, Razier JR, Abrey LE, Grefe CN, Lamborn K, Pao W, Shih AH, Wilson R, Nowak NJ, Cowell JK, DeAngelis LM, Wen P, Gilbert MR, Chang S, Yung WKA, Prados M, Holland EC Molecular study of malignant gliomas treated with the EGFR inhibitor erlotinib (OSI-774): tissue analysis from the North American Tumor Consortium (NABTC) trial 01-03 Clinical Cancer Research 11:7841-7850, 2005.
  • Chang S : Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme, Nature Clinical Practice Oncology- Practice Point 3, 70-71, 2006
  • Lee MC, Cha S, Chang SM, Nelson SJ. Partial-volume model for determining white matter and gray matter cerebral blood volume for analysis of gliomas. J Magn Reson Imaging 23:256-266 (2006).
  • Butowski N, Sneed P, Chang S : Diagnosis and management of recurrent malignant astrocytoma., J Clin Oncol- special issue 24: 1273-1280, 2006
  • Prados MD, Lamborn KR, Yung WAY, Jaeckle K, Robins HI, Mehta M, Fine H, Wen PY, Cloughesy T, Chang SM, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J. Phase 2 trial of irinotecan in patients with recurrent malignant glioma: A North American Brain Tumor Consortium Study. Neuro-Oncology 8: 189-193, 2006
  • Barker FG, Chang SM : Improving resection of malignant glioma. Lancet Oncology 7: 359-360, 2006
  • Chang S, Butowski N, Sneed P, Garner I : Standard Treatment and Experimental Targeted Drug Therapy for Recurrent Glioblastoma Multiforme. Neurosurgical Focus 20 (4):E4, 2006
  • Kunwar S, Chang SM, Prados MD, Berger MS, Croteau D, Sherman JW, Grahn A, Shu V, Dul J, Pedain C P, Puri RK : Intraparenchymal Convection-Enhanced Delivery: Safety Experience from Early Phase Studies with Cintredekin Besudotox. Neurosurgical Focus, 20(3):E15, 2006
  • Cloughesy TF, Wen P, Robins HI, Chang SM, Groves M, Fink K, Junck L, Schiff D, Abrey L, Gilbert M, Puduvalli V, Nicholas K, Conrad C, Grren berg H, Lieberman F, Kuhn J, DeAngelis LM, Burton E, Mehat M, Hess K, Torres-Trejo A, Raizer J, Yung WKA, Kuhn J, Lamborn K, Prados M : Phase II trial of Tipifarnib in patients with recurrent malignant glioma either on or not on enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium. J Clin Oncol 24:3651-3656, 2006
  • Tihan T, Barletta J, Parney I, Lamborn K, Sneed PK, Chang S : Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients following radiotherapy: should pathology evaluation alter treatment decisions? Human Pathology 37:272-82, 2006
  • Keles EG, Chang EF, Lamborn KR, Tihan T, Chang CJ, Chang SM, Berger MS : Volumetric extent of resection and residual contrast enhancement at initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J Neuro-surg 105:34-40, 2006
  • Prados MD, Lamborn KR, Chang SM, Burton E, Butowski N, Malec M, Kapadia A, Rabbitt J, Page M, Federoff A : Phase I study of erlotinib HCL alone and in combination with temozolomide in patients with stable or recurrent malignant glioma. Neuro-oncology 8:67-78, 2006